Arcutis Biotherapeutics announced the first subject has been enrolled in a Phase 1b study evaluating ARQ-255, a topical suspension of ivarmactinib, a potent and specific janus kinase 1 inhibitor, for the treatment of alopecia areata. ARQ-255 has been specifically formulated with Arcutis’ proprietary 4D technology to deliver drug deep into the skin to the base of the hair follicle, the site of the inflammation that underlies alopecia areata. "Alopecia areata is an immune condition that not only causes hair loss, but also causes significant negative impact on an individual’s emotional and mental wellbeing. Today, there are no FDA-approved topical therapies to treat the condition," said Frank Watanabe, President and CEO at Arcutis. "We are delighted to take this first step in the clinical development of ARQ-255, which leverages our unique 4D technology to deliver drug to the site of inflammation deep in the hair follicle."
Published first on TheFly
See Insiders’ Hot Stocks on TipRanks >>
Read More on ARQT:
- Arcutis Biotherapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
- Arcutis Biotherapeutics announces publication of data on roflumilast cream
- Arcutis Biotherapeutics Publishes First Environmental, Social, and Governance (ESG) Report
- CORRECTION — Arcutis Announces Positive Topline Results from INTEGUMENT-1 Pivotal Phase 3 Trial of Roflumilast Cream in Atopic Dermatitis in Adults and Children Aged Six Years and Older
- Arcutis to Present at Upcoming Investor Conference